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Frequency and Prognostic Significance of Preoperatively
Detected Enlarged Regional Lymph Nodes in Patients with
Pathological Stage I Non-small Cell Lung Cancer
Following Resection
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and Peter Goldstraw, FRCS§
Purpose: To explore the clinical significance of enlarged regional
lymph nodes in patients with pathological stage I non-small cell lung
cancer (NSCLC).
Material and Methods: We retrospectively reviewed the tumor
registry of the International Association for the Study of Lung
Cancer (IASLC) Staging Database to identify 6995 patients between
January 1, 1990 and December 31, 2000 with clinical stage I, II, and
IIIA tumors (cT1-2N0-2M0, excluding T3N0-2M0 cases) who
proved to have pathological stage I NSCLC (T1-2N0M0, pStage I).
The frequency of enlarged nodes in patients with pStage I disease is
reported, and the overall survival of these patients who had enlarged
regional lymph nodes was compared with that of patients with
pStage I disease with normal size regional lymph nodes.
Results: Enlarged regional lymph nodes (cN1-2) were seen in
approximately 12% of patients with pStage I disease. Median
survival for patients with enlarged versus normal nodes was 102
versus 107 months (hazard ratio 1.16, p  0. 01). Survival curves
converged at 8 years postsurgery.
Conclusions: Enlarged regional lymph nodes are uncommon in
patients with pStage I NSCLC, and the size of regional lymph nodes
in these early stage patients does not seem to provide clinically
useful prognostic information.
Key Words: Non-small cell lung cancer, Neoplasm staging, Lym-
phatic metastasis, Lymph nodes/pathology, Lymphangiogenesis,
Computed tomography, Prognosis, Survival analysis.
(J Thorac Oncol. 2007;2: 1103–1106)
Tumor stage at presentation plays an essential role indetermining prognosis and managing the treatment of
patients with a new diagnosis of non-small cell lung cancer
(NSCLC).1 Clinical staging of regional lymph nodes typically
relies on computed tomography (CT) of the chest, which uses
size as the sole criteria to suggest metastasis. Although larger
nodes have a greater probability for harboring tumor, the
overall accuracy of CT is only approximately 60%.2,3
Some patients with early-stage NSCLC have enlarged
regional lymph nodes that pathologically prove to be “reac-
tive.” The prognostic significance of nodal size in these
patients is uncertain. Recent studies in animal models have
shown that primary tumors stimulate nodal lymphangiogen-
esis, causing enlargement of regional nodes before metasta-
sis.4–8 These data suggested that patients with tumors and
enlarged nodes may have a worse prognosis than those
patients with normal size nodes, as the nodes were primed to
accept tumor cells. Alternatively, enlarged reactive nodes in
patients with early-stage disease can imply an immune re-
sponse to the tumor, thus potentially conferring a degree of
immunoprotection and improved outcomes.9,10
If the prognosis of pathological stage I (pStage I)
NSCLC with reactive nodal enlargement (cN1-2) was differ-
ent than that of patients with early-stage disease without
enlarged nodes (cN0), then management changes could be
made with the hope of improving outcomes. This retrospec-
tive study explored the International Association for the
Study of Lung Cancer (IASLC) database to evaluate the
prognostic significance of enlarged lymph nodes in patients
with pStage I NSCLC.
METHODS
Patient Population
This study was approved by the IASLC Lung Cancer
Staging Committee. A retrospective review of the tumor
registry of the IASLC Staging Database was undertaken to
identify all patients between January 1, 1990 and December
31, 2000 with clinical stage I, II (cT1-2N0-1M0 cases and
excluding cT3N0M0), and IIIA (cT1-2N2M0 cases excluding
cT3N1-2M0) who underwent resection and were proved to
have pStage I NSCLC.11 The study group of 6995 subjects
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included 4772 men and 2003 women (sex not documented for
220 patients) with a median age of 67 years (range, 19–90
years).
Clinical Staging, Pathological Staging,
Treatment, and Follow-Up
A clinical stage was assigned (cTNM) to all patients
based on a combination of imaging studies, including plain
chest radiographs and CT.
As per the entrance criteria, all patients had confirmed
pStage I NSCLC (pT1-2N0M0) after attempted resection. No
patient had preoperative therapy, although 222 of the 6995
patients were registered in databases submitted by clinical
trial groups, and 287 had postoperative chemo- and/or radio-
therapy. Follow-up data were recorded for all patients, with
95% followed at least 2 years or until death and 81%
followed for at least 5 years or until death.
Defining Lymph Node Status
Lymph node categories (N) were recorded according to
the AJCC Cancer Staging system,12 and regional nodes were
considered enlarged and abnormal if they were larger than 1
cm in short axis on CT. All cases confirmed to be pN1 or pN2
after resection and the pathological examination were ex-
cluded from further study.
Statistical Analysis
Kaplan-Meier survival curves were performed and com-
pared the survival probability between patients who had en-
larged regional lymph nodes (cN1-2) but pStage I, and patients
with normal size regional lymph nodes (cN0), and pStage I.
Additional analysis was performed according to histology.
These groups were compared with a log rank test generated
using the SAS System for Windows Version 9.0 PHREG pro-
cedure. The survival time was defined as the time between the
date of resection and the last follow-up or date of death.
RESULTS
Frequency of Enlarged Nodes among All
Patients with pStage I NSCLC
This retrospective review of the IASLC database iden-
tified 6995 patients, 4772 men and 2003 women (220 sex
unknown) with a mean age of 65 years (range, 19–90 years)
with pathological stage I NSCLC. Of these patients, 859
(12%) had enlarged regional lymph nodes by imaging criteria
and were designated as having clinical stage II or IIIA
(cT1-2N1-2M0) disease.
Enlarged Nodes in 859 Patients with pStage I
(cT1-2N1-2M0; pT1-2N0M0)
There were 704 men and 129 women (26 sex unknown)
with a mean age of 65 years (range, 33–83 years) reported to
have cN1 or N2 disease and thus clinical stage II (n  367)
or IIIA (n  492), but all were later proved to be pStage I
(Table 1).
The histology of the tumors is shown in Table 2. The
estimated median and 5-year survival are 107 months and
62%, respectively (Figure 1 and 2).
Normal Size Nodes in 6136 Patients with
Pathological Stage I Disease
(cT1-2N0M0; Pt1-2N0M0)
There were 4068 men and 1874 women (194 sex
unknown) with a mean age of 65 years (range, 19–90 years).
None of these patients was reported to have enlarged regional
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FIGURE 1. Survival for patients with pathological stage I
non-small cell lung cancer. Clinical N0 versus clinical N1–N2.
Median survival times were 102 and 107 months for pa-
tients with clinical stage I and II–IIIA (excluding T3N0M0), re-
spectively (hazard ratio 1.16, p  0.01), shown in the Kaplan-
Meier survival curve. The survival curves converge at 8 years
postsurgery. The 95% confidence limits for the median survival
time (MST) estimates are shown in parentheses.
TABLE 1. Overall Clinical Versus Pathological Stage
Clinical Stage Total
Pathological Stage
IA IB
Total 6995 3248 3747
IA 3277 2747 530
IB 2859 289 2570
IIA 79 54 25
IIB (T3 excluded) 288 26 262
IIIA (T3N1-2 excluded) 492 132 360
TABLE 2. Histology of Non-small Cell Lung Cancer
Total
Pathology N0 Clinical N0
Clinical
N1–N2
Total 6995 6136 859
Adenocarcinoma 3438 3119 319
BAC 303 287 16
Squamous 2748 2293 455
Large cell, NOS 291 252 39
Adenosquamous 92 73 19
Large cell, neuroendocrine 7 7 0
Mixed non-small cell 14 9 5
Non-small cell, NOS 102 96 6
BAC, bronchioalveolar carcinoma; NOS, not otherwise specified.
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lymph nodes and thus were both clinical and pathological
stage I (Table 1).
The histology of the tumors is shown in Table 2. The
estimated median and 5-year survival rates are 102 months
and 67%, respectively.
Statistical Comparison
Survival for patients with enlarged versus normal nodes
was statistically different favoring the cN0 patients (hazard
ratio 1.16, p  0.01), although the survival curves converge
at 8 years postsurgery (Figure 1). Analysis was also per-
formed according to histology. There was a statistically
significant difference in survival (RR 1.35, p  0.0017)
among nodal status groups for adenocarcinoma (including
bronchioaveolar carcinoma (BAC)), but no difference for
other histologies (Figure 3) in general and no difference
among squamous cases in particular (data not shown).
DISCUSSION
Non-invasive imaging plays an integral role in staging
and facilitating management in patients with a new diagnosis
of lung cancer. These studies typically include a thoracic CT
through the adrenal glands, a head CT or magnetic resonance
imaging, a bone scan, and, at many institutions, a positron
emission tomographic (PET) scan. The most common site of
lung cancer metastasis is the regional lymph nodes, which are
considered abnormal on CT when nodes are larger than 10
mm in diameter in short axis.2 However, it is well established
that benign reactive lymph nodes may be enlarged and
metastatic lymph nodes may be of normal size.3,13–15
When lymph nodes are enlarged on CT in patients with
a new diagnosis of NSCLC, they are considered to contain
metastasis, although 37% to 43% of enlarged lymph nodes on
CT are negative by pathological evaluation.13,14,16 Although
PET imaging may reduce the number of false-positive CT
scans,15,17,18 enlarged nodes are still usually biopsied before
resection. Thus, although imaging provides a road map to
target regional nodes sampled at mediastinoscopy or thora-
cotomy, it is not sufficient for making treatment decisions.
The clinical significance of enlarged reactive nodes
remains unclear. Some investigators have suggested that
non-malignant lymph node enlargement can be the result of
preexisting inflammatory processes. Alternatively, lymph
node expansion is attributed to the growth of new lymphatic
capillaries and dilatation of lymph sinuses and vessels that are
stimulated by tumor-secreted cytokines such as vascular en-
dothelial growth factors (VEGF)-A, -C, and –D.4–7,19–23 The
effect of lymphangiogenesis results in increased blood flow to
the lymph nodes, which can potentially increase seeding of
subsequent metastases.4–8 Lymphangiogenesis in NSCLC is
associated with an increased incidence of regional lymph
node metastasis.24–26 Furthermore, expression of VEGF-C
and -A in the primary NSCLC has be shown to be a signif-
icant prognostic factor.25 If this were the case, then one would
predict patients with enlarged, reactive nodes would do worse
than patients with normal sized nodes.
This study showed that enlarged nodes are uncommon
in patients with pathologically proved early-stage disease and
that overall survival differences in nodal size groups for all
patients with NSCLC are not clinically meaningful. Early
survival differences were observed among nodal size groups
in patients with adenocarcinoma; however, median survival
exceeded 10 years for these patients, and there was insuffi-
cient follow-up beyond 7 years for the patients with cN1-2
pN0 adenocarcinoma to reach conclusions about long-term
survival for this specific subgroup.
The overall findings most likely result from the fact that
lymph node enlargement can be caused by a spectrum of
diseases, not just tumors. Although enlarged nodes may have
been caused by the tumor, they may have predated the onset
of their NSCLC and be unrelated. Regardless, size of nodes
does not seem to be useful in stratifying patients with early-
stage NSCLC, and nodal sampling is required for accurate
pathological staging in all cases, irrespective of cN category.
This study has several fundamental limitations, partic-
ularly because the data were collected and analyzed retro-
FIGURE 2. Non-contrast computed tomography scan of
the thorax shows a cavitary right upper lobe non-small cell
lung cancer and enlarged right paratracheal (Station 4R)
lymph node (arrow). Mediastinoscopy was performed, and
there was no evidence of lymph node metastasis on patho-
logical evaluation. All nodes were reactive.
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FIGURE 3. Survival for pathological stage I according to
histology. Survival curves with 95% confidence limits for
the median survival time (MST) estimates are shown in
parentheses.
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spectively. Although this is the largest lung cancer database
ever recorded and standard terminology was requested, there
would be variations in nomenclature and classification. In
addition, whereas patients’ clinical stages were recorded, the
exact size of nodes is unknown, and we can only conclude
that patients with NSCLC and enlarged nodes do not have
any different outcome than patients without evidence for
adenopathy. Other limitations are that we only had overall
survival and did not have disease-specific survival data;
postsurgical treatment regimens were not uniform; there was
no standard requirement of nodal sampling at surgery; and
pathologic examination of reselected nodes varied among
institutions. Additional follow-up, which may shed further
light on the findings, has been requested.
In conclusion, despite these limitations, this study an-
alyzed a large number of patients from an international
database and found that enlarged regional lymph nodes in all
patients with pStage I NSCLC was uncommon and did not
have clear prognostic significance.
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